The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | The clinical relevance of MBL: impact on risk of developing lymphoid & other malignancies
Susan Slager, PhD, Mayo Clinic, Rochester, MN, briefly discusses the significance of monoclonal B-cell lymphocytosis (MBL), a common condition in asymptomatic individuals, which increases the risk of developing lymphoid malignancies, melanoma, and also impairs vaccination response. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
